We've merged with Palleos Healthcare to form a wide-reaching European CRO.
Find out more
OCT Clinical, a European CRO, is happy to announce that it has completed patient recruitment in an influenza vaccine study in record time.
This is a multicenter, double-blind, randomized phase III clinical trial that will run in two parallel groups. It aims to prove efficacy, safety and reactogenicity of the vaccine. The quadrivalent inactivated subunit adjuvanted influenza vaccine is developed by a full-cycle biopharmaceutical company with 20-years' successful experience in operating in the pharma market. The vaccine technology is unique and was developed twenty years ago.
Despite the tight schedule, the enrollment of 824 subjects was completed in record time. Participants include children aged from 6 to 35 months, who will be screened across 14 investigative centers. By now, vaccination of all volunteers has been completed, and the period of observation is underway.
'We are confident that our vast experience in influenza and vaccine studies will help us to provide our clients with qualified clinical services and reach all the milestones on time,' - Vitaly Gneyshev, Project Manager at OCT Clinical.
The OCT Clinical team is responsible for all aspects of conducting this study, including regulatory and logistics support, project management, site initiation and monitoring. This repeat business study is a result of previous successful collaboration between OCT Clinical and the Sponsor.
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
